Mining Polo-Box domain of Polo-like kinase 1 as a new therapeutic target for cancer.
- Author:
Zhenghao FU
1
;
Meihua SU
2
;
Xiaoping LIU
1
;
Yunyu CHEN
1
Author Information
- Publication Type:Review
- Keywords: Polo-Box domain; Polo-like kinase 1 inhibitor; allosteric agent; molecular targeted therapy; protein-protein interactions
- MeSH: Cell Cycle Proteins/genetics*; Neoplasms/drug therapy*; Protein Kinase Inhibitors/pharmacology*; Protein-Serine-Threonine Kinases/genetics*; Proto-Oncogene Proteins/genetics*
- From: Chinese Journal of Biotechnology 2020;36(11):2298-2312
- CountryChina
- Language:Chinese
- Abstract: Polo-like kinase 1 (Plk1) is widely regarded as one of the most promising targets for cancer therapy due to its essential role in cell division and tumor cell survival. At present, most Plk1 inhibitors have been developed based on kinase domain, some of which are in clinical trial. However, inhibitors targeting kinase domain face off-target effect and drug resistance owing to the conserved nature and the frequent mutations in the ATP-binding pocket. In addition to a highly conserved kinase domain, Plk1 also contains a unique Polo-Box domain (PBD), which is essential for Plk1's subcellular localization and mitotic functions. Inhibitors targeting Plk1 PBD show stronger selectivity and less drug resistance for cancer therapy. Therefore, Plk1 PBD is an attractive target for the development of anti-cancer agents. In this review, we will summarize the up-to date drug discovery for targeting Plk1 PBD, including the molecular structure and cellular functions of Plk1 PBD. Small-molecule inhibitors targeting Plk1 PBD not only provide an opportunity to specifically inhibit Plk1 activity for cancer treatment, but also unveil novel biological basis regarding the molecular recognition of Plk1 and its substrates.
